In this weeks British Medical Journal (BMJ), two groups of public health doctors argue for routine opt-out HIV testing in healthcare settings such as general practice surgeries, accident and emergency departments and hospital wards.
In the first article, professor Harold Jaffe and colleagues say that a third of people in the UK with HIV do not know they have the virus, yet UK guidelines recommend opt-out testing only for pregnant women and people attending genitourinary (GUM) clinics.
They argue that routine opt-out testing would not only give a more accurate picture of how many people have HIV, but would cut infection rates, lessen the stigma surrounding testing and reduce the number of people being diagnosed in the later stages of HIV.
They point to America where guidelines from the Centers for Disease Control and Prevention now recommend voluntary opt-out testing as the standard of care for people aged 13 to 64 years, unless the prevalence of HIV is less than 0.1 percent of the population.
They say programs for routine screening have been instituted in emergency departments and urgent care centers at several US hospitals and yielded relatively high rates of previously undiagnosed HIV infection.
About 20,000 UK residents between the ages of 15 and 59 were living with undiagnosed HIV infection in 2005.
Surveys of gay men attending GUM clinics in the same year showed the prevalence of undiagnosed HIV was 3.2 percent. In women of childbearing age that prevalence was much lower (0.09 percent), but was highest in women from sub-Saharan Africa (2.4 percent).
The authors therefore call for surveys to be carried out in areas of known increased HIV prevalence and in facilities that are known to serve people at increased risk of infection. This would provide the necessary data to inform a discussion of expanding opt-out HIV testing.
In view of the clear advantages of early diagnosis of HIV infection for public and individual health, we believe the effectiveness and feasibility of expanded opt-out testing should be seriously assessed, they conclude.
In the second article, researchers look at the situation in France, where the rate of HIV testing is among the highest in Europe, but 40 percent of people are still not diagnosed until the disease is advanced, either with AIDS or with a low CD4 cell count. Therefore, of the estimated 7,000 people newly diagnosed with HIV in France in 2004, 3,000 may have advanced disease.
This has a major impact on death rates and the spread of infection, say Cyrille Delpierre and colleagues. Each year, one fifth of HIV infected patients' deaths were patients who had discovered their infection in the year before their deaths.
While the current policy in France successfully targets at risk groups, they say it fails to reach low risk groups, who tend to be older, mainly men, heterosexual, with a partner and children. Low risk groups are the most likely to test late.
They say late testing could play an important role in the spread of the infection. Studies suggest that if someone knows they are infected they are more likely to use preventative measures, such as using a condom.
Late testing could also be associated with greater costs in hospital care and the management of opportunistic infections. Catching these people earlier could, they say, lead to a reduction of 31 percent a year in the number of new sexually transmitted infections.
They therefore recommend expanding routine voluntary HIV testing to all primary healthcare settings.
An accompanying editorial argues that a more precise goal for any changes in policy should be to reduce the average time between infection and diagnosis.
Source: BMJ
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.